Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
enGene Holdings Inc. Warrants (ENGNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ENGNW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 110.08% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.39 | 52 Weeks Range 0.42 - 2.74 | Updated Date 06/22/2025 |
52 Weeks Range 0.42 - 2.74 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.35% | Return on Equity (TTM) -33.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 26066719 |
Shares Outstanding - | Shares Floating 26066719 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
enGene Holdings Inc. Warrants
Company Overview
History and Background
enGene Holdings Inc. is a clinical-stage genetic medicines company focused on developing transformative genetic medicines for local administration to treat a wide range of diseases. The warrants analyzed here represent the right to purchase shares of enGene Holdings common stock at a specified price.
Core Business Areas
- Genetic Medicine Development: Focuses on developing and commercializing gene therapies for various diseases using their non-viral delivery platform.
Leadership and Structure
Information on enGene Holdings Inc.'s leadership team and organizational structure can be found on their investor relations page. The analysis here specifically concerns the warrants.
Top Products and Market Share
Key Offerings
- EG-70: Lead product candidate EG-70 Ofranergene obadenovec is an investigational immunotherapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and is currently in Phase 2 clinical trials. Competitors include Merck and UGN.
Market Dynamics
Industry Overview
The genetic medicines market is rapidly growing, driven by advancements in gene therapy technologies and increasing demand for effective treatments for genetic and acquired diseases.
Positioning
enGene Holdings is positioning itself as a leader in non-viral gene therapy delivery, focusing on local administration to address unmet medical needs.
Total Addressable Market (TAM)
The TAM for gene therapies is substantial and expected to continue growing. enGene is targeting specific disease areas within this broader market.
Upturn SWOT Analysis
Strengths
- Novel non-viral gene delivery platform
- Focus on local administration
- Experienced management team
Weaknesses
- Early stage of clinical development
- Reliance on single lead product candidate
- Significant funding requirements
Opportunities
- Potential to expand the application of its platform to other diseases
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results for EG-70
Threats
- Competition from other gene therapy companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MRK
- UGNX
Competitive Landscape
enGene's non-viral approach offers a potential advantage over viral vector-based therapies. However, it faces competition from established players with more advanced pipelines and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily focused on advancing EG-70 through clinical trials and developing its non-viral delivery platform.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of its products. Analyst estimates can provide further details. The warrant price is directly tied to the common stock price.
Recent Initiatives: Recent initiatives include ongoing clinical trials for EG-70 and exploration of new indications for its gene therapy platform.
Summary
enGene is a clinical-stage company focused on non-viral gene therapy. Its warrants provide leveraged exposure to the company's stock. Success hinges on clinical trial outcomes and regulatory approvals. Potential investors should carefully consider the risks associated with investing in early-stage biotechnology companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- enGene Holdings Inc. SEC Filings
- Company Website
- Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The warrant's value is derived from the value of the underlying common stock, and is therefore influenced by the company's performance and other related factors. Investing in warrants involves substantial risk, including the risk of total loss.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enGene Holdings Inc. Warrants
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.engene.com |
Full time employees 56 | Website https://www.engene.com | ||
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.